T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged cord blood cells take on resistant blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…
Matched conditions: T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered cells take on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …
Matched conditions: T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Matched conditions: T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…
Matched conditions: T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial tests a new treatment called Senza5 CART5 for people with a type of T cell lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to better target and attack cancer cells. The main goal …
Matched conditions: T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Vittoria Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC